Claims
- 1. In a dermatological preparation containing a dermatological base, a drug, and a percutaneous absorption promoting agent, the improvement wherein the percutaneous absorption promoting agent comprises (A) at least one anionic surfactant and (B) at least one surfactant having a nitrogen atom in the molecule other than anionic and cationic surfactants as the active ingredients, the mole ratio of the components (A)/(B) being 20/1 to 1/20.
- 2. A dermatological preparation as claimed in claim 1, wherein the ratio (A)/(B) is 10/1 to 1/10.
- 3. In a dermatological preparation containing a dermatological base, a drug, and a percutaneous absorption promoting agent, the improvement wherein the percutaneous absorption promoting agent comprises (A) at least one surfactant selected from the group consisting of amphoteric surfactants and semi-polar surfactants and (B) at least one nonionic surfactant having a nitrogen atom in the molecule as the active ingredients, the mole ratio of the components (A)/(B) being 20/1 to 1/20.
- 4. A dermatological preparation as claimed in claim 3, wherein the ratio (A)/(B) is 10/1 to 1/10.
- 5. A preparation according to claim 1, wherein A comprises sodium dodecylsulfate and B comprises dodecylaminoacetic acid betaine.
- 6. A dermatological preparation according to claim 1, wherein (A) is selected from the group consisting of a carboxylic acid, a sulfonic acid, a sulfuric acid ester and a phosphoric acid ester or salt thereof, and (B) is selected from the group consisting of a fatty acid alkanolamide, polyoxyethylene fatty acid amide, ester of an alkanolamine, polyoxyethylene alkylamine, a carboxyl betaine, an imidazoline derivative, an aminocarboxylic acid salt, a sulfobetaine, an aminobetaine and an amine oxide.
- 7. A dermatological preparation according to claim 1, wherein (A) is selected from the group consisting of a fatty acid soap, an acyl glutamate, sulfosuccinic acid, ether sulfonic acid salt, a amidosulfuric acid salt and alkylphosphoric acid salt, and (B) is selected from the group consisting of a fatty acid alkanolamide, polyoxyethylene fatty acid amide, ester of an alkanolamine, polyoxyethylene alkylamine, N,N-dimethyl-N-lauryl-N-carboxyl-methylammonium betaine, N,N-dimethyl-N-oleyl-N-carboxymethylammonium betaine, 2-lauryl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, 2-lauryl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, N-cocoalkyl-.beta.-aminopropionic acid sodium salt, N-cocoalkyl-.beta.-iminodipropionic acid disodium salt, sulfobetaine, aminobetaine, lauryldimethylamine oxide, stearyldimethylamine oxide, bis-(2-hydoxyethyl)laurylamine oxide, an N-acylsulfonic acid salt and an alkyl sulfonic acid salt.
- 8. A dermatological preparation according to claim 3, wherein (A) is selected from the group consisting of a carboxyl betaine, an imidazoline derivative, an aminocarboxylic acid salt, a sulfobetaine, an aminobetaine and an amine oxide, and (B) is a fatty acid alkanolamide.
- 9. A dermatological preparation according to claim 3, wherein (A) is selected from the group consisting of N,N-dimethyl-N-lauryl-N-carboxyl-methylammonium betaine, N,N-dimethyl-N-oleyl-N-carboxymethyl ammonium betaine, 2-lauryl-N-carboxymethyl-N-hydroxyethyl-imidazolinium betaine, 2-lauryl-N-carboxymethyl-N-hydroxyethyl-imidazolinium betaine, N-cocoalkyl-.beta.-aminopropionic acid sodium salt, N-cocoalkyl-.beta.-iminodipropionic acid disodium salt, sulfobetaine, aminobetaine, lauryldimethylamine oxide, stearyldimethylamine oxide and bis-(2-hydroxyethyl)laurylamine oxide, and (B) is a fatty acid alkanolamide.
- 10. A dermatological preparation according to claim 6, wherein (B) includes a chain of 8 to 24 carbon atoms.
- 11. In a dermatological preparation containing a dermatological base, a drug, and a percutaneous absorption promoting agent, the improvement wherein the percutaneous absorption promoting agent consists essentially of an amine oxide selected from the group consisting of:
- (1) water-insoluble or only slightly water-soluble amine oxides represented by the formula (I): ##STR4## wherein R.sub.1, R.sup.2 and R.sup.3 each represents a straight or branched alkyl group or alkenyl group having 1 to 24 carbon atoms, and at least one of R.sub.1, R.sub.2 and R.sub.3 represents a straight or branched alkyl group or alkenyl group having 16 to 24 carbon atoms;
- (2) dihydroxyethylalkylamine oxides represented by the formula (II): ##STR5## wherein R represents a straight or branched alkyl group or alkenyl group having 8 to 24 carbon atoms; and
- (3) dimethylalkylpolyoxyethyleneamine oxides represented by the formula (III): ##STR6## wherein R represents a straight or branched alkyl group or alkenyl group having 8 to 24 carbon atoms, and n represents an integer from 1 to 5.
- 12. A dermatological preparation according to claim 11, wherein the amine oxide has a stearyl radical.
- 13. A dermatological preparation according to claim 11 wherein the amine oxide has a behenyl radical.
Priority Claims (4)
Number |
Date |
Country |
Kind |
62-39756 |
Feb 1987 |
JPX |
|
62-43954 |
Feb 1987 |
JPX |
|
62-65297 |
Mar 1987 |
JPX |
|
62-65298 |
Mar 1987 |
JPX |
|
Parent Case Info
This application is a continuation, of application Ser. No. 850,325, filed as PCT/JP88/00187, Feb. 22, 1988 now abandoned, which is a division of U.S. application Ser. No. 298,610, filed Oct. 5, 1988 now U.S. Pat. No. 5,120,716.
US Referenced Citations (9)
Foreign Referenced Citations (5)
Number |
Date |
Country |
2714477 |
Jan 1979 |
AUX |
2223583 |
Jun 1984 |
AUX |
0038512 |
Oct 1981 |
EPX |
0046594 |
Mar 1982 |
EPX |
2359165 |
Feb 1978 |
FRX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
298610 |
Oct 1988 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
850325 |
Mar 1992 |
|